Last reviewed · How we verify
OTX-TKI (axitinib implant)
OTX-TKI (axitinib implant) is a tyrosine kinase inhibitor that targets vascular endothelial growth factor receptors.
OTX-TKI (axitinib implant) is a tyrosine kinase inhibitor that targets vascular endothelial growth factor receptors. Used for Metastatic renal cell carcinoma.
At a glance
| Generic name | OTX-TKI (axitinib implant) |
|---|---|
| Sponsor | Ocular Therapeutix, Inc. |
| Drug class | tyrosine kinase inhibitor |
| Target | VEGFR |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
By inhibiting these receptors, OTX-TKI reduces angiogenesis and tumor growth. This mechanism is particularly effective in treating cancers that are dependent on vascular endothelial growth factor for growth and survival.
Approved indications
- Metastatic renal cell carcinoma
Common side effects
- Hypertension
- Diarrhea
- Fatigue
Key clinical trials
- A Study to Evaluate the Efficacy and Safety of OTX-TKI (Axitinib Implant) in Participants With Non-Proliferative Diabetic Retinopathy (PHASE3)
- Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Axitinib Implant) in Subjects With Neovascular Age- Related Macular Degeneration (PHASE3)
- Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (Axitinib Implant) in Subjects With Neovascular Age-Related Macular Degeneration (PHASE3)
- Study Evaluating the Treatment of OTX-TKI for Subjects With Neovascular Age-related Macular Degeneration (PHASE1)
- Study to Evaluate the Safety, Tolerability, and Efficacy of OTX-TKI in Subjects With Moderately Severe to Severe Non-proliferative Diabetic Retinopathy (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- OTX-TKI (axitinib implant) CI brief — competitive landscape report
- OTX-TKI (axitinib implant) updates RSS · CI watch RSS
- Ocular Therapeutix, Inc. portfolio CI